While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
The incubator, housed on the campus of the Karolinska Institute, draws upon the experience of its partners in genomics, diagnostics, business development, and corporate law.
Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.
The study lends support to the case for dried blood spots as a proteomics sample source for applications like biobanking and longitudinal patient monitoring.
Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.
The company said its new Massachusetts office will focus on driving US sales of its Proseek Multiplex platform for targeted human protein biomarker discovery.
The new company, Olink Proteomics, will focus on the Proseek Platform for protein detection, while the remaining firm will look to commercialize other parts of its IP portfolio.
Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
Based on Olink's proximity ligation technology, Duolink allows for detection of low-abundance proteins with higher specificity than conventional immunoassays.
ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.
The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.
CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.
In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.